The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHOC 2022 | Using CEC levels to evaluate treatment outcomes of splanchnic vein thrombosis in chronic MPNs
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of a study which used circulating endothelial cells (CECs) to evaluate treatment outcomes of splanchnic vein thrombosis in patients with chronic myeloproliferative neoplasms (MPNs). This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
